PI-House Clinical Trial Center
Site in Gdańsk, acting under the brand of PI House, became a part of Penta Hospitals Poland in mid-2024. It has been operating for many years, becoming a specialized research center, focused on developing therapies in psychiatry, neurology, dermatology, metabolic diseases, and rheumatology.
For over a decade, we have completed over 250 clinical trials at the Gdańsk Clinical Research Center. Together with a team of 35 experienced and dedicated specialists, we conduct approximately 60 active research projects annually, combining clinical expertise with attentiveness to participants’ needs.
As one of the most experienced sites in Poland specializing in trials in the area of a central nervous system (CNS), since 2011 we have been a trusted partner for pharmaceutic companies, CROs, and patients.
We conduct clinical trials in the following therapeutic areas:
- Adult Psychiatry;
- Child and Adolescent Psychiatry;
- Neurology;
- Adult Dermatology;
- Child and Adolescent Dermatology;
- Metabolic Disorders;
- Rheumatology.
As the first private site in Poland, we have started trials using control substances, including psychedelic substances — in a dedicated to that therapeutic space, in compliance with ethical and regulatory requirements.
In January 2026, the PI-House Clinical Research Center expanded its operations by opening a new branch at ul. Wyspiańskiego 25 (80-434 Gdańsk), established in cooperation with the NeuroVitalis clinic. This expansion forms part of a long-term strategy to develop research infrastructure and strengthen expertise in the fields of neurology, psychiatry, and pain management. The new location enables the implementation of clinical projects on a larger scale, including new indications such as multiple sclerosis and Parkinson’s disease, while maintaining full operational oversight, high quality standards, and regulatory compliance.


